Discover
CYCN
Cyclerion Therapeutics, Inc.
3.56
1 x 2.43
2 x 4.60
bid
ask
+
0.07
2.01%
01:19 PM
timesize
| Ytd | 180.31% | |
| 1y | 7.88% |
3.35
day range
3.46
1.03
52 week range
8.48
| Open | 3.44 | Prev Close | 3.49 | Low | 3.35 | High | 3.46 | Mkt Cap | 14.96M |
| Vol | 5.55K | Avg Vol | 199.73K | EPS | -1.31 | P/E | N/A | Forward P/E | -2.44 |
| Beta | 1.92 | Short Ratio | 0.78 | Inst. Own | 40.41% | Dividend | N/A | Div Yield | N/A |
| Ex Div Date | N/A | Earning | 08-11 | 50-d Avg | 3.15 | 200-d Avg | 2.18 | 1yr Est | 4.00 |
Earning
| Date | For | Estimate | Reported | Surprise | surprise % |
|---|---|---|---|---|---|
| 2024-11-14 | 2024-09 | 0 | -0.29 | N/A | N/A |
| 2024-08-07 | 2024-06 | 0 | -0.53 | N/A | N/A |
| 2024-05-07 | 2024-03 | 0 | -0.62 | N/A | N/A |
| 2024-03-27 | 2023-12 | 0 | N/A | N/A | N/A |
| 2023-11-13 | 2023-09 | 0 | -0.93 | N/A | N/A |
| 2023-07-28 | 2023-06 | 0 | -1.83 | N/A | N/A |
Upgrade / Downgrade
| Date | Firm | Action | From | To |
|---|
Profile
Cyclerion Therapeutics, Inc., a biopharmaceutical company, develops treatments for serious diseases. It is developing Olinciguat, an orally administered vascular soluble guanylate cyclase (sGC) stimulator, which is in Phase 2 clinical trial to out-license for cardiovascular diseases; and Praliciguat, a systemic sGC stimulator that is licensed to Akebia Therapeutics, Inc. for the treatment of rare kidney disease. The company was incorporated in 2018 and is headquartered in Cambridge, Massachusetts.
Insider Holder
| Date | Name | Relation | Quantity | Description |
|---|---|---|---|---|
| 2023-11-29 | DESOUZA ERROL B | Director | 30.00K | Stock Award(Grant) |
| 2023-12-28 | GRAUL REGINA MARGARET | President | 100.30K | Stock Award(Grant) |
| 2023-12-28 | HECHT PETER M | Director and Beneficial Owner of more than 10% of a Class of Security | 377.46K | Stock Award(Grant) |
| 2023-11-29 | HYMAN STEVEN | Director | 20.00K | Stock Award(Grant) |
| 2023-11-29 | MCGUIRE TERRANCE G | Director | 42.01K | Stock Award(Grant) |
| 2024-11-20 | SLATE PATH CAPITAL LP | Beneficial Owner of more than 10% of a Class of Security | 0.00 | Sale |
Institution Ownership
| Report Date | Organization | Position | Value | Percentage |
|---|---|---|---|---|
| 2024-09-29 | Slate Path Capital, LP | 357.88K | 1.15M | 13.21% |
| 2024-09-29 | MFN Partners Management, LP | 169.46K | 542.27K | 6.25% |
| 2024-09-29 | Tyndall Capital Partners LP | 164.78K | 527.29K | 6.08% |
| 2024-09-29 | FMR, LLC | 157.64K | 504.44K | 5.82% |
| 2024-09-29 | Siren, L.L.C. | 116.16K | 371.70K | 4.29% |
| 2024-09-29 | Geode Capital Management, LLC | 33.91K | 108.51K | 1.25% |
Fund Ownership
| Report Date | Organization | Position | Value | Percentage |
|---|---|---|---|---|
| 2024-09-29 | Vanguard Extended Market Index Fund | 23.49K | 75.17K | 0.87% |
| 2024-10-30 | Fidelity Growth Company Fund | 20.56K | 65.80K | 0.76% |
| 2024-10-30 | Fidelity NASDAQ Composite Index ETF | 14.08K | 45.05K | 0.52% |
| 2024-10-30 | Fidelity Extended Market Index Fund | 10.83K | 34.64K | 0.40% |
| 2024-10-30 | Fidelity Growth Company K6 Fund | 9.22K | 29.50K | 0.34% |
| 2024-10-30 | Fidelity Series Total Market Index Fund | 2.33K | 7.44K | 0.09% |
Split
| Split | Date |
|---|---|
| 1 : 20 | 2023-05-16 |